Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01251159|
Recruitment Status : Completed
First Posted : December 1, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: mutation analysis Genetic: polymerase chain reaction Other: immunologic technique Other: laboratory biomarker analysis|
- To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML).
- To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations.
- To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur.
OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Somatic Mutations in Stem and Progenitor Cells in AML|
|Actual Study Start Date :||May 15, 2009|
|Actual Primary Completion Date :||June 15, 2009|
|Actual Study Completion Date :||June 15, 2009|
- Define somatic mutations occurring in de novo AML [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01251159
|Principal Investigator:||Ulrich G. Steidl, MD, BS||Albert Einstein College of Medicine, Inc.|